Vanguard Group Inc. Raises Stock Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Vanguard Group Inc. raised its stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 40.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 34,009,994 shares of the company's stock after purchasing an additional 9,737,196 shares during the quarter. Vanguard Group Inc. owned 8.70% of Recursion Pharmaceuticals worth $229,908,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently modified their holdings of the company. State Street Corp raised its position in Recursion Pharmaceuticals by 47.1% in the 3rd quarter. State Street Corp now owns 12,870,272 shares of the company's stock valued at $84,815,000 after buying an additional 4,120,685 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Recursion Pharmaceuticals by 13.7% in the 3rd quarter. Geode Capital Management LLC now owns 5,431,911 shares of the company's stock worth $35,803,000 after acquiring an additional 656,003 shares in the last quarter. Institute for Wealth Management LLC. purchased a new stake in shares of Recursion Pharmaceuticals in the fourth quarter valued at about $3,928,000. Platinum Investment Management Ltd. lifted its position in shares of Recursion Pharmaceuticals by 293.9% during the fourth quarter. Platinum Investment Management Ltd. now owns 733,011 shares of the company's stock valued at $4,955,000 after purchasing an additional 546,929 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in Recursion Pharmaceuticals by 17.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 2,274,003 shares of the company's stock worth $15,372,000 after purchasing an additional 333,323 shares during the last quarter. Institutional investors own 89.06% of the company's stock.

Remove Ads

Analyst Ratings Changes

Several equities analysts have commented on RXRX shares. Cowen reissued a "hold" rating on shares of Recursion Pharmaceuticals in a research report on Friday, February 28th. KeyCorp reduced their price objective on Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating for the company in a research note on Wednesday, January 8th. Morgan Stanley lowered their target price on Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating on the stock in a research note on Thursday. Leerink Partners decreased their price objective on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating for the company in a report on Friday, February 28th. Finally, Needham & Company LLC reissued a "buy" rating and set a $11.00 target price on shares of Recursion Pharmaceuticals in a research report on Tuesday. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $8.20.

Recursion Pharmaceuticals Stock Performance

Recursion Pharmaceuticals stock traded down $0.14 during midday trading on Thursday, reaching $4.51. The stock had a trading volume of 29,307,555 shares, compared to its average volume of 11,420,401. The firm has a market capitalization of $1.81 billion, a PE ratio of -2.95 and a beta of 1.00. Recursion Pharmaceuticals, Inc. has a 12 month low of $3.79 and a 12 month high of $12.36. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04. The firm's 50-day moving average price is $6.87 and its 200 day moving average price is $6.84.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last announced its quarterly earnings results on Friday, February 28th. The company reported ($0.53) EPS for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.17). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The business had revenue of $4.60 million for the quarter, compared to analysts' expectations of $19.04 million. During the same quarter in the previous year, the company posted ($0.42) earnings per share. The business's quarterly revenue was down 57.8% compared to the same quarter last year. As a group, research analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.